Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 81 to 90 of 858 total matches.
A New Snake Antivenom
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001 (Issue 1107)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba
EDITORIAL FELLOWS: Elizabeth Stephens, M.D ...
CroFab, an antigen-binding-fragment (Fab) antivenom of ovine origin, has been approved by the FDA for treatment of North American rattlesnake envenomation.
Arrhythmias From Droperidol?
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002 (Issue 1132)
) and the antihistamines terfenadine (Seldane)
and astemizole (Hismanal) (F De Ponti et al, Drug Saf 2002; 25:263 ...
The FDA has added a "black box" warning about the risks of QT prolongation and the potentially fatal torsades de pointes (TdP) ventricular tachycardia to the labeling of droperidol (Inapsine - Akorn), an antiemetic used mostly in anesthesia. The Canadian Health Protection Branch has issued a similar warning. Some anesthesiologists have written to The Medical Letter to express their displeasure with these warnings.
In Brief: Fluoroquinolones and Tendon Injuries
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
patients.
4
1. F Muzi et al. Fluoroquinolones-induced tendinitis and tendon
rupture in kidney transplant ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
In Brief: Different Diets
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009 (Issue 1308)
., Albert Einstein College of Medicine
Sandip K. Mukherjee, M.D. F.A.C.C., Yale School of Medicine
Jordan ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
In Brief: Cardiac Risks of Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • Feb 23, 2009 (Issue 1306)
, M.D. F.A.C.C., Yale School of Medicine
Jordan W. Smoller, M.D., Sc.D., Harvard Medical School ...
A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death. Typical antipsychotics have long been associated with this risk. In this study, however, the incidence of sudden cardiac death was similar with typical and atypical antipsychotics: about 1 in 340 person-years among the patients who took typical (first generation) antipsychotics such as haloperidol (Haldol, and others) and 1 in 360 personyears among those who took atypical...
Bimatoprost 0.03% Solution (Latisse) for Eyelash Enhancement
The Medical Letter on Drugs and Therapeutics • Jun 01, 2009 (Issue 1313)
.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie ...
The FDA has approved the prostaglandin analog bimatoprost in a 0.03% solution (Latisse - Allergan) for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes.
Red Yeast Rice
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS ...
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Hyperbaric Oxygen Therapy for Refractory Wounds
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie ...
Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.
A Morphine/Naltrexone Combination (Embeda) for Pain
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie Pflomm, Pharm.D ...
The FDA has approved an agonist/antagonist combination of morphine and naltrexone (Embeda – King)
for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended
period of time. The addition of naltrexone is intended to prevent abuse of morphine.
Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie ...
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in chronic kidney disease and may be associated with decreased absorption from the gastrointestinal tract, limiting the usefulness of oral iron replacement. IV iron replacement can lower the dose requirement for erythropoiesis-stimulating drugs, particularly in patients on dialysis